Search

Zentalis Pharmaceuticals Inc

Avatud

3.48 -0.57

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.42

Max

3.55

Põhinäitajad

By Trading Economics

Sissetulek

-42M

-78M

Aktsiakasum

-0.59

Töötajad

106

EBITDA

-42M

-77M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+151.66% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

6. nov 2026

Turustatistika

By TradingEconomics

Turukapital

47M

378M

Eelmine avamishind

4.05

Eelmine sulgemishind

3.48

Zentalis Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. sept 2026, 23:51 UTC

Brazil's Business Confidence Index (ICEI) for September 2026 set to release on September 14, with cautious optimism amid persistent pessimism and geopolitical challenges.

13. sept 2026, 23:41 UTC

GBP/AUD shows notable strength in after-market trading, reaching a cumulative return peak of 0.17% since Friday's close, with no specific news identified.

13. sept 2026, 23:41 UTC

Correlated Moves

EUR/AUD is higher in after-market trading, diverging from the lower Nasdaq 100 Index amid heightened Fed interest rate hike expectations following a strong consumer price index report.

13. sept 2026, 23:31 UTC

China's House Price Index YoY release on September 15, 2026, is anticipated to reveal ongoing weakness in the housing sector amid cautious optimism from recent policy measures.

13. sept 2026, 23:31 UTC

U.S. Building Permits Forecasted at 1.41 Million for August Amid Stable Market Sentiment Ahead of September Release

13. sept 2026, 23:31 UTC

Upcoming U.S. Housing Starts Data Release on September 17 Expected to Influence Economic Outlook Amidst Market Fluctuations.

13. sept 2026, 23:31 UTC

U.S. Housing Starts Expected to Recover Slightly to 1.32 Million Units Amid Ongoing Concerns Over High Mortgage Rates and Recent Declines

13. sept 2026, 23:31 UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Positive Sentiment and Anticipated Growth, Forecasted at 30.0

13. sept 2026, 23:31 UTC

U.S. Building Permits Data Set for Release on September 17, 2026, Amid Cautious Optimism in Housing Market Sentiment

13. sept 2026, 23:31 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in August Amid Cautious Optimism on Consumer Spending

13. sept 2026, 23:31 UTC

Retail Sales MoM report for August 2026 set to release on September 16, with a forecasted increase of 0.9% amid cautious consumer spending sentiment following July's unexpected decline.

13. sept 2026, 23:31 UTC

U.S. Import Prices MoM data for August 2026 set to release on September 16, with a modest increase of 0.2% expected amid inflation concerns and potential Fed interest rate adjustments.

13. sept 2026, 23:31 UTC

U.S. Export Prices MoM Release on September 16 Expected to Impact Monetary Policy Amidst Recent Price Decline and Mixed Market Sentiment

13. sept 2026, 23:21 UTC

Macro News
News

Bitcoin is lower as U.S.-China tensions rise and crude oil prices fall. Regulatory optimism around the Bitcoin and Crypto Clarity Act fails to boost sentiment.

13. sept 2026, 23:11 UTC

EUR/NZD is trading lower during after-market hours, settling at -0.11%. The currency pair remains above its 20-day moving average.

13. sept 2026, 23:01 UTC

EUR/JPY trades higher in after-market hours, recovering from earlier lows amid expectations for a Federal Reserve interest rate hike on September 16.

13. sept 2026, 23:01 UTC

Correlated Moves

The AUD/USD is lower during after-market hours, reflecting declines in the Nasdaq 100 Index and influenced by recent consumer price index data.

13. sept 2026, 23:01 UTC

Macro News
Correlated Moves

Geopolitical tensions with China and domestic electricity concerns contribute to a decline in the Dow Jones Index, which has reached a session low below its 20-day moving average.

13. sept 2026, 23:01 UTC

Macro News
Correlated Moves

U.S.-China tensions rise over arms deals with Taiwan, impacting market sentiment. The S&P 500 Index is trading lower today, reflecting broader market weakness.

13. sept 2026, 23:01 UTC

Macro News

Geopolitical tensions are driving WTI prices higher as concerns about U.S.-China relations and Iranian pressures on Saudi Arabia impact global oil markets.

13. sept 2026, 23:01 UTC

Correlated Moves

The Russell 2000 Index is lower today, continuing a downward trend amid broader market sentiment influenced by rising core CPI data and Fed rate hike expectations.

13. sept 2026, 23:01 UTC

Correlated Moves

Platinum is trading lower, influenced by a decline in silver prices amid rising consumer inflation and expectations for a Federal Reserve interest rate hike.

13. sept 2026, 23:01 UTC

EUR/SEK is trading lower during after-market hours, reflecting a slight decline since Friday's close. The asset remains near its one-month range high.

13. sept 2026, 23:01 UTC

Correlated Moves

Silver prices are lower, influenced by gold's decline and inflation data. The asset remains below its 20-day moving average amid market pressures.

13. sept 2026, 23:01 UTC

The Nasdaq 100 Index is lower amid ongoing market weakness, following a consumer price index report that exceeded expectations and heightened rate hike speculation.

13. sept 2026, 23:01 UTC

Natural Gas is trading higher, continuing gains from Friday's close. Prices reached their highest point during the session, with no specific news identified.

13. sept 2026, 23:01 UTC

EUR/CZK is trading lower in after-market hours, reflecting a modest decline since Friday's close amid solidified market expectations for a Federal Reserve interest rate hike.

13. sept 2026, 23:01 UTC

Macro News
Correlated Moves

Gold prices are lower as market expectations grow for a Federal Reserve interest rate hike. Goldman Sachs anticipates a 25 basis-point increase at the FOMC meeting.

13. sept 2026, 23:01 UTC

Ethereum is trading lower, continuing a downward trend since Saturday's close. The asset reached a session low earlier today.

13. sept 2026, 22:51 UTC

Canada's Housing Starts Data Release on September 16 Expected to Show Continued Weakness Amid Economic Pressures

Võrdlus sarnastega

Hinnamuutus

Zentalis Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

151.66% tõus

12 kuu keskmine prognoos

Keskmine 8.833 USD  151.66%

Kõrge 11 USD

Madal 5 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Zentalis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

5

Osta

1

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat